CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment - PubMed

Affiliations

• PMID: 16269611
• DOI: 10.1182/blood-2005-08-3182

Free article

Review

CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment

Jan A Burger et al. Blood. 2006.

Free article

Abstract

Signals from the microenvironment have a profound influence on the maintenance and/or progression of hematopoietic and epithelial cancers. Mesenchymal or marrow-derived stromal cells, which constitute a large proportion of the non-neoplastic cells within the tumor microenvironment, constitutively secrete the chemokine stromal cell-derived factor-1 (SDF-1/CXCL12). CXCL12 secretion by stromal cells attracts cancer cells, acting through its cognate receptor, CXCR4, which is expressed by both hematopoietic and nonhematopoietic tumor cells. CXCR4 promotes tumor progression by direct and indirect mechanisms. First, CXCR4 is essential for metastatic spread to organs where CXCL12 is expressed, and thereby allows tumor cells to access cellular niches, such as the marrow, that favor tumor-cell survival and growth. Second, stromal-derived CXCL12 itself can stimulate survival and growth of neoplastic cells in a paracrine fashion. Third, CXCL12 can promote tumor angiogenesis by attracting endothelial cells to the tumor microenvironment. CXCR4 expression is a prognostic marker in various types of cancer, such as acute myelogenous leukemia or breast carcinoma. Promising results in preclinical tumor models indicate that CXCR4 antagonists may have antitumor activity in patients with various malignancies. Collectively, these observations reveal that CXCR4 is an important molecule involved in the spread and progression of a variety of different tumors. As such, CXCR4 antagonists, although initially developed for treatment of AIDS, actually may become effective agents for the treatment of neoplastic disease.

Similar articles

• Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.

  Nazari A, Khorramdelazad H, Hassanshahi G. Nazari A, et al. Int J Clin Oncol. 2017 Dec;22(6):991-1000. doi: 10.1007/s10147-017-1187-x. Epub 2017 Oct 11. Int J Clin Oncol. 2017. PMID: 29022185 Review.

• Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer.

  Dewan MZ, Ahmed S, Iwasaki Y, Ohba K, Toi M, Yamamoto N. Dewan MZ, et al. Biomed Pharmacother. 2006 Jul;60(6):273-6. doi: 10.1016/j.biopha.2006.06.004. Epub 2006 Jun 28. Biomed Pharmacother. 2006. PMID: 16828253 Review.

• Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion.

  Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. Orimo A, et al. Cell. 2005 May 6;121(3):335-48. doi: 10.1016/j.cell.2005.02.034. Cell. 2005. PMID: 15882617

• Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis.

  Pan J, Mestas J, Burdick MD, Phillips RJ, Thomas GV, Reckamp K, Belperio JA, Strieter RM. Pan J, et al. Mol Cancer. 2006 Nov 3;5:56. doi: 10.1186/1476-4598-5-56. Mol Cancer. 2006. PMID: 17083723 Free PMC article.

• The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis.

  Wang J, Loberg R, Taichman RS. Wang J, et al. Cancer Metastasis Rev. 2006 Dec;25(4):573-87. doi: 10.1007/s10555-006-9019-x. Cancer Metastasis Rev. 2006. PMID: 17165132 Review.

Cited by

• A biomimetic targeted nanosystem delivering synergistic inhibitors for glioblastoma immune microenvironment reprogramming and treatment.

  Mu Y, Zhang Z, Zhou H, Jin M, Ma L, Liu B, Ma C, Hu X, Zhang Y, Wang DA. Mu Y, et al. Mater Today Bio. 2024 Sep 1;28:101222. doi: 10.1016/j.mtbio.2024.101222. eCollection 2024 Oct. Mater Today Bio. 2024. PMID: 39296357 Free PMC article.

• Developing Nanoceria-Based pH-Dependent Cancer-Directed Drug Delivery System for Retinoblastoma.

  Gao R, Mitra RN, Zheng M, Wang K, Dahringer JC, Han Z. Gao R, et al. Adv Funct Mater. 2018 Dec 27;28(52):1806248. doi: 10.1002/adfm.201806248. Epub 2018 Nov 12. Adv Funct Mater. 2018. PMID: 32699541 Free PMC article.

• CXC chemokine ligand 12/stromal cell-derived factor-1 regulates cell adhesion in human colon cancer cells by induction of intercellular adhesion molecule-1.

  Tung SY, Chang SF, Chou MH, Huang WS, Hsieh YY, Shen CH, Kuo HC, Chen CN. Tung SY, et al. J Biomed Sci. 2012 Oct 25;19(1):91. doi: 10.1186/1423-0127-19-91. J Biomed Sci. 2012. PMID: 23098564 Free PMC article.

• Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.

  Cui B, Zhang S, Chen L, Yu J, Widhopf GF 2nd, Fecteau JF, Rassenti LZ, Kipps TJ. Cui B, et al. Cancer Res. 2013 Jun 15;73(12):3649-60. doi: 10.1158/0008-5472.CAN-12-3832. Cancer Res. 2013. PMID: 23771907 Free PMC article.

• CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers.

  Misra AC, Luker KE, Durmaz H, Luker GD, Lahann J. Misra AC, et al. Biomacromolecules. 2015 Aug 10;16(8):2412-7. doi: 10.1021/acs.biomac.5b00653. Epub 2015 Jul 22. Biomacromolecules. 2015. PMID: 26154069 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • Guide to Pharmacology

• Research Materials

  • NCI CPTC Antibody Characterization Program